Pilot Study of the Safety and Efficacy of Carvedilol in Pulmonary Arterial Hypertension

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

10 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-06-30

Study Completion Date

2014-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine whether carvedilol treatment of patients with pulmonary arterial hypertension and associated right heart failure is safe and results in an improved function of the right heart.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Carvedilol PAH A Pilot Study of Efficacy and Safety

NCT02120339

Pulmonary Hypertension Cardiac MRI <40

TERMINATED PHASE1

Beta-blockers in Pulmonary Arterial Hypertension

NCT02507011

Pulmonary Arterial Hypertension

TERMINATED PHASE2

PAHTCH Pulmonary Arterial Hypertension Treatment With Carvedilol for Heart Failure (Carvedilol)

NCT01586156

Pulmonary Hypertension

COMPLETED NA

Clevidipine for Vasoreactivity Evaluation of the Pulmonary Arterial Bed

NCT01121458

Hypertension, Pulmonary

COMPLETED PHASE4

Carbon Monoxide Therapy for Severe Pulmonary Arterial Hypertension

NCT01523548

Hypertension, Pulmonary

WITHDRAWN PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients with pulmonary arterial hypertension (PAH) will be treated with carvedilol for 24 weeks. During this time, carvedilol will be titrated from an initial dose of 3.125mg BID to a maximal dose of 25mg BID. At the start and end of the study, we will obtain cardiac MRI, 6 minute walk distance, brain natriuretic peptide (serum), echocardiogram, and functional class assessment. Our primary outcome is a change in right ventricular ejection fraction with cardiac MRI.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pulmonary Arterial Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

carvedilol

Carvedilol is titrated from a dose of 3.125mg twice daily to a maximal dose of 25mg twice daily over 24 weeks. Patients are evaluated to their response with 6 minute walk testing, echocardiography, and cardiac MRI

Group Type EXPERIMENTAL

Carvedilol

Intervention Type DRUG

twice daily oral treatment in escalating dose

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Carvedilol

twice daily oral treatment in escalating dose

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Coreg

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* idiopathic, familial or associated PAH, WHO group 1
* NYHA class II or III
* clinically stable with optimized PAH treatment for at least 3 months
* no or minimal evidence of fluid overload or volume depletion, with or without diuretic treatment
* age \> 18 years
* mean pulmonary artery pressure (mPAP) \> 25 mmHg
* 6 minute walk distance (6MWD) over 100m

Exclusion Criteria

* Structural heart disease unrelated to PAH
* Recent (\<3 months) treatment with an intravenous positive inotropic agent
* current use of β-blockers
* history of reactive airways disease
* history of adverse reaction to β-blockers
* heart block on ECG or resting heart rate \< 60 bpm
* cardiac index \< 1.8 l/min/m2
* systemic hypotension (systolic pressure \< 90 mmHg)
* pulmonary capillary wedge pressure \> 15 mmHg
* inability to give informed consent
* contraindications to CT and/or PET scanning
* coagulopathy (INR\>1.5 or platelet count\<50000/mm3)
* severe renal insufficiency (creatinine clearance \<30 ml/min/m2)
* malignancy or any co-morbidity limiting survival or conditions predicting inability to complete the study.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No